- AU$738.75m
- AU$881.22m
- $0.12m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5,360.5 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -437.07% | ||
| Return on Equity | n/a | ||
| Operating Margin | -268713.7% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.06 | 0.07 | 0.09 | 0.11 | 0.12 | 0.14 | 41.36 | 1.86% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
Directors
- Jeremy Levin NEC (68)
- Megan Baldwin CEO
- Karen Adams VFN
- Richard Chadwick OTH
- Mike Gerometta OTH
- Annette Leahy OTH
- Ian Leitch OTH
- Clare Price OTH
- Judith Robertson OTH (61)
- Lawrence Gozlan NID
- Julia Haller NID (66)
- Michael Sistenich NID
- Daniel Spiegelman NID (62)
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 17th, 1984
- Public Since
- April 9th, 1985
- No. of Shareholders
- 7,809
- No. of Employees
- 5
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 1,231,250,867
- Address
- Suite 0403, MELBOURNE, 3141
- Web
- https://opthea.com/
- Phone
- +61 398260399
- Auditors
- Deloitte Touche Tohmatsu
Upcoming Events for OPT
Similar to OPT
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Opthea share price?
As of Today at 22:27 UTC, shares in Opthea are trading at AU$0.60. This share price information is delayed by 15 minutes.
How has the Opthea share price performed this year?
Shares in Opthea last closed at AU$0.60 and the price had moved by -5.51% over the past 365 days. In terms of relative price strength the Opthea share price has underperformed the ASX All Ordinaries Index by -6.92% over the past year.
What are the analyst and broker recommendations for Opthea?
The overall consensus recommendation for Opthea is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Opthea dividend yield?
Opthea does not currently pay a dividend.
Does Opthea pay a dividend?
Opthea does not currently pay a dividend.
When does Opthea next pay dividends?
Opthea does not currently pay a dividend.
How do I buy Opthea shares?
To buy shares in Opthea you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Opthea?
As of the previous close price of AU$0.60, shares in Opthea had a market capitalisation of AU$738.75m.
Where are Opthea shares listed?
Here are the trading details for Opthea:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: OPT
What kind of share is Opthea?
Based on an overall assessment of its quality, value and momentum Opthea is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Opthea share price forecast for 2025?
The analyst consensus target price for shares in Opthea is AU$6.12. That is 919.79% above the last closing price of AU$0.60.
Analysts covering Opthea currently have a consensus Earnings Per Share (EPS) forecast of -$0.16 for the next financial year.
Find out moreWhat is the trend in the Opthea share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Opthea. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +3.09%.
As of the last closing price of AU$0.60, shares in Opthea were trading -11.58% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Opthea PE Ratio?
The Opthea PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Opthea?
Opthea's management team is headed by:
- Jeremy Levin - NEC
- Megan Baldwin - CEO
- Karen Adams - VFN
- Richard Chadwick - OTH
- Mike Gerometta - OTH
- Annette Leahy - OTH
- Ian Leitch - OTH
- Clare Price - OTH
- Judith Robertson - OTH
- Lawrence Gozlan - NID
- Julia Haller - NID
- Michael Sistenich - NID
- Daniel Spiegelman - NID